Evidence map›Paper›PMID 40377111›Full record

ArticleJournal of medicinal chemistry2025

Medicinal Chemistry Progression of Sapanisertib, the Anticancer and Dual

Samuel Gachuhi, Stephanie Kamunya, Stephen Fienberg, Lynn Wambua, Nicolaas Salomane, Godfrey Mayoka, Dale Taylor, Dina Coertzen, Mariette van der Watt, Janette Reader and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Samuel GachuhiDepartment of Chemistry, University of Cape Town, Rondebosch ,7701 Cape Town, South Africa.
Stephanie KamunyaDepartment of Chemistry, University of Cape Town, Rondebosch ,7701 Cape Town, South Africa.
Stephen FienbergHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, 7701 Cape Town, South Africa.
Lynn WambuaDepartment of Chemistry, University of Cape Town, Rondebosch ,7701 Cape Town, South Africa.
Nicolaas SalomaneHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, 7701 Cape Town, South Africa.
Godfrey MayokaDepartment of Chemistry, University of Cape Town, Rondebosch ,7701 Cape Town, South Africa.ORCID 0000-0003-2238-1249
Dale TaylorHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, 7701 Cape Town, South Africa.
Dina CoertzenDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, 0028 Pretoria, South Africa.
Mariette van der WattDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, 0028 Pretoria, South Africa.
Janette ReaderDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, 0028 Pretoria, South Africa.
Lyn-Marié BirkholtzDepartment of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Hatfield, 0028 Pretoria, South Africa.ORCID 0000-0001-5888-2905
Sergio WittlinSwiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland.ORCID 0000-0002-0811-0912
Liezl KrugmannHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, 7701 Cape Town, South Africa.
Lauren B CoulsonHolistic Drug Discovery and Development (H3D) Centre, University of Cape Town, Rondebosch, 7701 Cape Town, South Africa.ORCID 0000-0003-4699-0428
Kelly ChibaleDepartment of Chemistry, University of Cape Town, Rondebosch ,7701 Cape Town, South Africa.ORCID 0000-0002-1327-4727

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently demonstrated that the anticancer human mTOR inhibitor sapanisertib displays antimalarial activity in a malaria mouse model of infection and inhibits multiple

Indexed as

1-Phosphatidylinositol 4-KinaseAntimalarialsAntineoplastic AgentsCyclic GMP-Dependent Protein KinasesMalariaProtein Kinase InhibitorsPyrazolesPyrimidinesAnimalsHumansMicePlasmodium bergheiStructure-Activity Relationship1-Phosphatidylinositol 4-KinaseAntimalarialsAntineoplastic AgentsCyclic GMP-Dependent Protein KinasesProtein Kinase InhibitorsPyrazolesPyrimidines

Identifiers

PMID40377111
PMCPMC12169674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.